Adenosine Receptor A3 (ADORA3) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Adenosine Receptor A3 (ADORA3)- Pipeline Review, H2 2019’, provides in depth analysis on Adenosine Receptor A3 (ADORA3) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Gastrointestinal, Immunology, Metabolic Disorders, Ophthalmology, Genito Urinary System And Sex Hormones, Male Health, Central Nervous System, Musculoskeletal Disorders, Oncology, Respiratory and Women’s Health under development targeting Adenosine Receptor A3 (ADORA3).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)

– The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects

– The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Acorn Biomedical Inc

BioIntervene Inc

Can-Fite BioPharma Ltd

Future Medicine Co Ltd

Palo BioFarma SL”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Adenosine Receptor A3 (ADORA3) - Overview

Adenosine Receptor A3 (ADORA3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development

Can-Fite BioPharma Ltd

Future Medicine Co Ltd

Palo BioFarma SL

Adenosine Receptor A3 (ADORA3) - Drug Profiles

ACN-1052 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-1888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-2698 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

namodenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-1650 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piclidenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adenosine Receptor A3 (ADORA3) - Dormant Products

Adenosine Receptor A3 (ADORA3) - Discontinued Products

Adenosine Receptor A3 (ADORA3) - Product Development Milestones

Featured News & Press Releases

Sep 04, 2018: Top line results of the Namodenoson phase II advanced liver cancer trial expected by end of year

Aug 23, 2018: Can-Fite enrolls first patient in Phase III Comfort trial for psoriasis

Jul 17, 2018: Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug

Jul 02, 2018: Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer

Jun 19, 2018: Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial

Jun 11, 2018: Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson

Jun 11, 2018: Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson

Apr 25, 2018: Can-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research'

Apr 09, 2018: Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)

Mar 14, 2018: Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference

Mar 06, 2018: Can-Fite to Provide Update on its Lead Drug Candidate Piclidenoson in NASH at the 30th Annual ROTH Conference

Mar 06, 2018: Can-Fite to Provide Update on Liver Drug Namodenoson at the 30th Annual ROTH Conference

Feb 28, 2018: Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson

Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Piclidenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile

Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Acorn Biomedical Inc, H2 2019

Pipeline by BioIntervene Inc, H2 2019

Pipeline by Can-Fite BioPharma Ltd, H2 2019

Pipeline by Future Medicine Co Ltd, H2 2019

Pipeline by Palo BioFarma SL, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports